Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 481 to 495 of 973 results for death

  1. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

    Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    17 February 2021
    View recommendations

    Sections for TA673

  2. Elafibranor for previously treated primary biliary cholangitis (TA1016)

    Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.

    Technology appraisal guidance
    Published
    14 November 2024
    View recommendations

    Sections for TA1016

  3. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

    Technology appraisal guidance
    Published
    3 May 2023
    View recommendations

    Sections for TA882

  4. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

    Technology appraisal guidance
    Published
    14 August 2024
    View recommendations

    Sections for TA995

  5. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417

  6. Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

    Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA406

  7. Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (TA1116)

    Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.

    Technology appraisal guidance
    Published
    11 December 2025
    View recommendations

    Sections for TA1116

  8. Does early review and referral to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their life?

    identification and/or achievement of patient wishes such as preferred place of death Source guidance details Comes from guidance...

    Research recommendation
    Published
    10 August 2021

  9. What are the long-term benefits and harms, and cost effectiveness of endoscopic ultrasound (EUS) compared with magnetic resonance cholangiopancreatography (MRCP) in adults with suspected common bile duct stones?

    However, EUS carries a small but significant risk of patient harms, including death. There is insufficient evidence available to...

    Research recommendation
    Published
    9 June 2015

  10. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

    Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.

    Technology appraisal guidance
    Published
    15 August 2023
    View recommendations

    Sections for TA912

  11. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)

    Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.

    Technology appraisal guidance
    Published
    28 April 2021
    View recommendations

    Sections for TA694

  12. Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the diagnostic accuracy of serial C-reactive protein testing to identify chorioamnionitis in women with P-PROM?

    particularly important given that sepsis is a common direct cause of maternal death. There is currently limited evidence that serial...

    Research recommendation
    Published
    11 December 2015

  13. Recognising that a child or young person may be dying:- What signs and symptoms indicate that a child or young person with a life-limiting condition is likely to die within hours or days?

    are often asked to estimate how close a child or young person may be to death. There is very little evidence on which to base any such...

    Research recommendation
    Published
    15 February 2017

  14. Communication:- What are the most clinically effective and cost-effective methods of addressing patient and carer concerns about strong opioids, including anticipating and managing adverse effects, and engaging patients in prescribing decisions?

    especially morphine, can be negatively associated with adverse effects and death. To improve adherence and to enable patients and carers...

    Research recommendation
    Published
    9 June 2015

  15. Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)

    Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.

    HealthTech guidance
    Published
    6 May 2025
    View recommendations

    Sections for HTG747